Overview

Efficacy and Biomarker Explanation of AK-112 + Lenvatinib Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Status:
Not yet recruiting

Trial end date:
2024-04-01

Target enrollment:

Participant gender:

Summary

This study aimed to explore the efficacy and biomarker explanation of AK112 combined with Lenvatinib plus platinum based chemotherapy on ALK-rearranged non-small cell lung cancer who failed from first line Alectinib.

Phase:

Phase 2

Details

Lead Sponsor:

Hunan Province Tumor Hospital

Treatments:

Lenvatinib